LRCH1 suppresses migration of CD4+ T cells and refers to disease activity in ulcerative colitis.

Conclusion: LRCH1 plays an important role in the pathogenesis of UC, possibly through modulating the migration of CD4+ T cells. Therefore, targeting LRCH1 might serve as a novel therapeutic approach in the management of UC. PMID: 32210709 [PubMed - in process]
Source: International Journal of Medical Sciences - Category: Biomedical Science Tags: Int J Med Sci Source Type: research

Related Links:

Conclusions: In this real-life prospective cohort using dose optimization, thiopurines were safe and effective in 21% of CD and 27% of UC patients, including normalization of C-reactive protein and erythrocyte sedimentation rate. Thiopurines remain a viable option in the treatment algorithm of mild-moderate pediatric IBD, especially in girls whose risk for lymphoma is lower.
Source: Journal of Pediatric Gastroenterology and Nutrition - Category: Gastroenterology Tags: Original Articles: Gastroenterology: Inflammatory Bowel Disease Source Type: research
Publication date: 15 September 2020Source: Journal of Ethnopharmacology, Volume 259Author(s): Yumeng Shen, Junfeng Zou, Mengjun Chen, Zhimiao Zhang, Chen Liu, Shu Jiang, Dawei Qian, Jin-Ao Duan
Source: Journal of Ethnopharmacology - Category: Drugs & Pharmacology Source Type: research
Authors: D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S Abstract INTRODUCTION: Ulcerative colitis (UC) is a type of inflammatory bowel disease (IBD) affecting the large intestine and carrying a heavy burden of morbidity for patients. Conventional treatment is based on mesalamine, corticosteroids, and immunosuppressants. In the last two decades, biologic therapies have revolutionized the treatment of UC, increasing the number of therapeutic options and providing better disease control. AREAS COVERED: Most biologics have been approved in recent years and long-term data are still scarce. The aim of t...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Conclusions: Health-related quality of life was most prominently associated with bowel frequency during daytime, urgency of defecation, and blood in stool. Other symptoms associated for some health-related quality of life dimensions, and appear to vary between the sexes. PMID: 32442051 [PubMed - as supplied by publisher]
Source: Scandinavian Journal of Gastroenterology - Category: Gastroenterology Tags: Scand J Gastroenterol Source Type: research
Publication date: August 2020Source: Journal of Functional Foods, Volume 71Author(s): Junhua Jin, Siqi Wu, Yuanhong Xie, Hui Liu, Xiuzhi Gao, Hongxing Zhang
Source: Journal of Functional Foods - Category: Nutrition Source Type: research
Condition:   Ulcerative Colitis Interventions:   Other: Specific Carbohydrate Diet;   Other: Mediterranean Diet Sponsor:   Massachusetts General Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: Journal of Inflammation Research - Category: Allergy & Immunology Tags: Journal of Inflammation Research Source Type: research
In this study, we aimed to explore the effect of TrkB-PLC/IP3 pathway on intestinal inflammatory factors and enterocyte apoptosis in mice with colitis. The mouse model of ulcerative colitis was established by medication, and 40 SPF C57BL/6J mice (8 weeks old) were randomly divided into normal group (healthy mice, n = 10), control group (sham-operated mice, n = 10), model group (model mice without any treatment, n = 10), and K252a group (model mice treated with 100 μmol/kg TrkB-PLC/IP3 pathway inhibitor for 5 days before clysis, n = 10). The results s...
Source: Acta Biochimica et Biophysica Sinica - Category: Biochemistry Authors: Tags: Acta Biochim Biophys Sin (Shanghai) Source Type: research
DiscussionThe etrolizumab phase  3 clinical program is the largest and most comprehensive in inflammatory bowel disease, enrolling more than 3000 patients. The program explores both induction and maintenance regimens. HIBISCUS I and II and GARDENIA are among the first head-to-head trials in UC against an anti-TNF and are the fir st registrational trials making that comparison. This program will also help address unanswered clinical questions on evaluation of treatment effects and treatment selection across a range of patients with varying treatment histories using an extensive repository of patient samples and da...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
Condition:   Ulcerative Colitis Interventions:   Other: Specific Carbohydrate Diet;   Other: Mediterranean Diet Sponsor:   Massachusetts General Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biomedical Science | Inflammatory Bowel Disease | Ulcerative Colitis